Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C Albera
M27 Effect of Pirfenidone on Breathlessness as Measured by the Ucsd-Sobq Score in Patients With Idiopathic Pulmonary Fibrosis (Ipf) With Moderate Lung Function Impairment
M32 Effect of Pirfenidone on All-Cause Mortality (Acm) and Forced Vital Capacity (Fvc) in Idiopathic Pulmonary Fibrosis (Ipf) Patients With Low FVC and/or Low Dlco: Analysis of Pooled Data From Ascend and Capacity
Related publications
Analysis of Patients With Idiopathic Pulmonary Fibrosis (IPF) With More Severe Lung Function Impairment Treated With Pirfenidone in Recap
Chest
Cardiology
Critical Care
Cardiovascular Medicine
Intensive Care Medicine
Pulmonary
Respiratory Medicine
Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis and More Advanced Lung Function Impairment
Respiratory Medicine
Pulmonary
Respiratory Medicine
Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis
Annals of Thoracic Surgery
Respiratory Medicine
Pulmonary
Cardiovascular Medicine
Surgery
Cardiology
Efficacy of Pirfenidone in Patients With Advanced-Stage Idiopathic Pulmonary Fibrosis
Internal Medicine
Internal Medicine
Medicine
Prs41 - Cost-Effectiveness of Pirfenidone for the Treatment of Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Idiopathic Pulmonary Fibrosis and Pirfenidone
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Pirfenidone Should Be Prescribed for Patients With Idiopathic Pulmonary Fibrosis: Table 1
Thorax
Pulmonary
Respiratory Medicine
Comparison of the Antifibrotic Effects of the Pan-Histone Deacetylase-Inhibitor Panobinostat Versus the IPF-drug Pirfenidone in Fibroblasts From Patients With Idiopathic Pulmonary Fibrosis
PLoS ONE
Multidisciplinary
P196 Healthcare Utilisation by Patients With Idiopathic Pulmonary Fibrosis; Observations From the UK Pirfenidone Named Patient Programme
Thorax
Pulmonary
Respiratory Medicine
